Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) have received a consensus rating of “Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $94.57.
A number of research analysts recently issued reports on LMAT shares. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research lifted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, Oppenheimer restated an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st.
Check Out Our Latest Report on LMAT
Insider Transactions at LeMaitre Vascular
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its stake in shares of LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 293 shares during the period. CBIZ Investment Advisory Services LLC boosted its holdings in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 117 shares during the last quarter. NBC Securities Inc. grew its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the period. GAMMA Investing LLC raised its position in LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares during the period. Finally, KBC Group NV boosted its stake in shares of LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 410 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.
LeMaitre Vascular Stock Up 0.5 %
Shares of LMAT opened at $98.44 on Tuesday. The stock has a market capitalization of $2.21 billion, a P/E ratio of 53.79, a PEG ratio of 2.19 and a beta of 0.96. LeMaitre Vascular has a twelve month low of $58.66 and a twelve month high of $109.58. The firm has a fifty day simple moving average of $96.58 and a two-hundred day simple moving average of $93.28.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Further Reading
- Five stocks we like better than LeMaitre Vascular
- Health Care Stocks Explained: Why You Might Want to Invest
- Merck: 4 No-Brainer Reasons to Buy This Dip
- 3 Tickers Leading a Meme Stock Revival
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Trading Halts Explained
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.